Genetic testing company 23andMe is back in the business of direct-to-consumer health testing kits, after a two-year semi-hiatus (in the U.S., at least) from offering health risk assessments at the behest of the Food and Drug Administration. That makes 23andMe the first such company to win FDA approval for taking its…
23andMe quickly gained notoriety by providing private customers with health and ancestry information directly from their sequenced DNA, then, in 2013, it was stopped from providing health details by the FDA. Now it’s got the green light to resume.
Five years after privacy advocates warned about the potential risks to privacy posed by massive genetics databases, they are, indeed, causing problems. Two popular geneology websites, Ancestry.com and 23andMe, both maintain such databases on behalf of private citizens. Now there’s at least one case on record of…
23andMe made a name for itself selling DNA test kits, but today it announced a radical new direction: The company will start mining its huge database of DNA sequences to create new drugs. The science of how they could do that is fascinating—but it raises a lot of futuristic ethical questions too.
DNA testing startup 23andMe has been doing brisk business collecting genetic samples from over 800,000 customers. But the company just announced a new plan that'll launch it into the big pharma world: 23andMe is going to invent its own pharmaceutical drugs using the data it collects from customer DNA.
Back in 2013, the FDA forced 23andme to pull its DNA testing kits in the United States, saying the personal genetics company was offering an untested diagnostic device. Now the FDA has given the okay for 23andme to test for one specific genetic disorder — a potential sign that the company's full offering may stage a…
Today, 23andMe announced what Forbes reports is only the first of ten deals with big biotech companies: Genentech will pay up to $60 million for access to 23andMe's data to study Parkinson's. You think 23andMe was about selling fun DNA spit tests for $99 a pop? Nope, it's been about selling your data all along.
Following demands issued by the Food and Drug Administration late last month, 23andMe has ceased all health-related genetic testing until further notice.
The FDA has given personal genetics company 23andme 15 days to comply with health regulations, before the federal agency begins seizing the company's DNA testing kits. The FDA says 23andme is offering an untested "diagnostic" device in violation of the Federal Food, Drug and Cosmetic Act.
Something's not quite right about 23andMe's DNA analysis kits, and the Food and Drug Administration is on it. The agency ordered 23andMe to stop selling the kits until the Google-backed company can prove that they actually work. Sounds reasonable.
Mapping out your genome is the 21st Century equivalent of staring deep inside your soul; it's tempting to look, but terrifying what you might find. The DNA divers at 23andMe are hoping that slashing the price of their home-testing service—from $300 down to $100—will be enough to tilt the scales towards discovery. Are…
23andMe's DNA analysis kit doesn't cost $200 today. Rather, it's free. So, now that the super steep price can't scare you away from a deep analysis of your genetic past and future, is it worth it? Gizmodo's opinion is divided.
From $199 to $0—23andMe's DNA-analyzing service has been a subject on Gizmodo before, so if you were wondering what your chances of cancer, Alzheimer's or other illnesses are but were put off by the price, today's the day to act.
A mother wanted to discover her son's risk for certain diseases, so she mailed a DNA sample to genetics testing company 23and Me. The results made her cry: Her child's genetic profile was entirely inconsistent with his family's. What happened?
Walgreens plans to sell genetic testing kits for the first time in brick and mortar stores, but the FDA thinks this shift from labs/internet to pharmacy may be too much too fast.
At the advice of many medical experts, I'm leaving the following article, in which I'll discuss my personal probabilities of disease based upon my genetics, unsigned.
Gene-sequencing technology is taking off, but George Church at Harvard University is taking it to the next level: he wants to sequence the genomes of 100,000 people. Right now, about 12 human genomes have been sequenced and Church's ambitious plan is likely to cost cost around $1 billion to complete. Recently Google —…
Everybody is buzzing about 23andme, one of many startups aiming to hit the consumer market with "read your own genome at home" kits. Most of these companies want to cross the happy-personalization language of the iPod with barely-there biotech to bring in millions of customers. People are desperate to understand…